Events & Presentations Corporate Presentation Corporate Presentation - May 2026 May 12, 2026 DDW 2026: XmAb412: A Novel, High-Affinity, Anti-TL1A x Anti-IL23(p19) Native-Like Bispecific Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease May 5, 2026 DDW 2026: XmAb942, a Novel Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease: Phase 1 Final Results May 4, 2026 AACR 2026: XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells to enhance anti-tumor activity of clinically active CD3 T cell engagers April 17, 2026 Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) October 24, 2025 ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis February 19, 2025 ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy December 9, 2024 UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease October 10, 2024 Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells April 10, 2021 Events BofA Securities Health Care Conference 2026 May 12, 2026 at 3:00 PM PDT Listen to webcast Xencor DDW 2026 Webcast: XmAb942 and XmAb412 May 05, 2026 at 8:00 AM EDT Listen to webcast Supporting Materials Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update 1.6 MB Scientific Presentations DDW 2026: XmAb412: A Novel, High-Affinity, Anti-TL1A x Anti-IL23(p19) Native-Like Bispecific Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease May 5, 2026 DDW 2026: XmAb942, a Novel Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease: Phase 1 Final Results May 4, 2026 AACR 2026: XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells to enhance anti-tumor activity of clinically active CD3 T cell engagers April 17, 2026 Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) October 24, 2025 ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis February 19, 2025 ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy December 9, 2024 UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease October 10, 2024 Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells April 10, 2021
DDW 2026: XmAb412: A Novel, High-Affinity, Anti-TL1A x Anti-IL23(p19) Native-Like Bispecific Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease May 5, 2026
DDW 2026: XmAb942, a Novel Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease: Phase 1 Final Results May 4, 2026
AACR 2026: XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells to enhance anti-tumor activity of clinically active CD3 T cell engagers April 17, 2026
Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) October 24, 2025
ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis February 19, 2025
ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy December 9, 2024
UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease October 10, 2024
Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells April 10, 2021
Xencor DDW 2026 Webcast: XmAb942 and XmAb412 May 05, 2026 at 8:00 AM EDT Listen to webcast Supporting Materials Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update 1.6 MB
DDW 2026: XmAb412: A Novel, High-Affinity, Anti-TL1A x Anti-IL23(p19) Native-Like Bispecific Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease May 5, 2026
DDW 2026: XmAb942, a Novel Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease: Phase 1 Final Results May 4, 2026
AACR 2026: XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells to enhance anti-tumor activity of clinically active CD3 T cell engagers April 17, 2026
Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) October 24, 2025
ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis February 19, 2025
ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy December 9, 2024
UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease October 10, 2024
Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells April 10, 2021
